General Information of Drug (ID: DMC7HIS)

Drug Name
G749 Drug Info
Synonyms G-749
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
78357765
CAS Number
CAS 1457983-28-6
TTD Drug ID
DMC7HIS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [2]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [3]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [4]
RXDX-106 DM6NVTR Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
MRX-2843 DMM5N8P Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PF-07265807 DMSMNRQ Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
INCB81776 DMFOXGB Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
LDC1267 DMH7R6L Discovery agent N.A. Investigative [9]
UNC2025 DMCU59W Glioblastoma of brain 2A00.00 Investigative [10]
UNC569 DMJL6ZM Acute lymphoblastic leukaemia 2A85 Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [12]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [13]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [14]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [15]
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [16]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [17]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [12]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [3]
Lestaurtinib DMQ2AIJ Acute myeloid leukaemia 2A60 Approved (orphan drug) [18]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [1]
Tyrosine-protein kinase Mer (MERTK) TTO7LKR MERTK_HUMAN Inhibitor [1]

References

1 G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
2 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Ono Pharmaceutical.
5 National Cancer Institute Drug Dictionary (drug name RXDX106).
6 The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
7 National Cancer Institute Drug Dictionary (drug name PF-07265807).
8 A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
9 The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
10 MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
11 UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
18 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
19 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.